The first CAR T cells have been approved in Europe, following results from an international JULIET trial of 81 patients with relapsed and refractory DLBCL. According to study investigators, about a third of patients who fail current therapies, including transplant, could now be offered a form of therapy that may offer them remissions, relieve symptoms and save lives. These new and exciting ways of treating cancer are explained further in this Medscape article.